prikaz prve stranice dokumenta Procjena rizika prijeloma u bolesnika s kroničnom opstrukcijskom plućnom bolesti
  Download
PDF 563.4 KB
master's thesis
Procjena rizika prijeloma u bolesnika s kroničnom opstrukcijskom plućnom bolesti
Split: University of Split, School of Medicine, 2021. urn:nbn:hr:171:008510
Sušac, Vanja
University of Split
School of Medicine

Institutional repository: MEFST Repository

Cite this document

Sušac, V. (2021). Procjena rizika prijeloma u bolesnika s kroničnom opstrukcijskom plućnom bolesti (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:008510

Sušac, Vanja. "Procjena rizika prijeloma u bolesnika s kroničnom opstrukcijskom plućnom bolesti." Master's thesis, University of Split, School of Medicine, 2021. https://urn.nsk.hr/urn:nbn:hr:171:008510

Sušac, Vanja. "Procjena rizika prijeloma u bolesnika s kroničnom opstrukcijskom plućnom bolesti." Master's thesis, University of Split, School of Medicine, 2021. https://urn.nsk.hr/urn:nbn:hr:171:008510

Sušac, V. (2021). 'Procjena rizika prijeloma u bolesnika s kroničnom opstrukcijskom plućnom bolesti', Master's thesis, University of Split, School of Medicine, accessed 27 December 2024, https://urn.nsk.hr/urn:nbn:hr:171:008510

Sušac V. Procjena rizika prijeloma u bolesnika s kroničnom opstrukcijskom plućnom bolesti [Master's thesis]. Split: University of Split, School of Medicine; 2021 [cited 2024 December 27] Available at: https://urn.nsk.hr/urn:nbn:hr:171:008510

V. Sušac, "Procjena rizika prijeloma u bolesnika s kroničnom opstrukcijskom plućnom bolesti", Master's thesis, University of Split, School of Medicine, Split, 2021. Available at: https://urn.nsk.hr/urn:nbn:hr:171:008510

Metadata
TitleProcjena rizika prijeloma u bolesnika s kroničnom opstrukcijskom plućnom bolesti
Title (english)Fracture risk assesment in patients with chronic obstructive pulmonary disease
AuthorVanja Sušac
MentorSuzana Mladinov (mentor)
Committee memberIvan Gudelj (predsjednik povjerenstva)
Committee memberJoško Božić (član povjerenstva)
Committee memberIvana Pavlinac Dodig (član povjerenstva)
GranterUniversity of Split
School of Medicine
Split
Defense date and country2021-07-27, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Internal Medicine
Abstract
Cilj: Cilj ovoga rada bio je procijeniti rizik prijeloma u pacijenata s kroničnom opstrukcijskom plućnom bolesti (KOPB) s obzirom na specifične čimbenike rizika vezane uz bolest, a povezane s razvojem osteoporoze i prijeloma. Ispitanici i metode: Istraživanje je provedeno u Klinici za plućne bolesti Kliničkog bolničkog centra Split tijekom travnja i svibnja 2021. godine. Sudjelovalo je 35 ispitanika oboljelih od KOPB-a. Podatci su prikupljeni anketnim upitnicima i uvidom u medicinsku dokumentaciju. Za svakog ispitanika izračunat je desetogodišnji rizik za prijelome pomoću alata FRAX. Pacijenti su uspoređivani po skupinama ovisno o broju akutnih egzacerbacija u prethodnoj godini dana, ukupnoj dnevnoj dozi inhalacijskih kortikosteroida i stupnju bronhalne opstrukcije prema GOLD-u. Rezultati: Usporedbom pacijenata koji su imali visok rizik za razvoj akutnih egzacerbacija s onima niskog rizika nije dobivena statistički značajna razlika rizika prijeloma kuka P=0,420 i velikog osteoporotskog prijeloma P=0,398. Iako je rizik za prijelom kuka u skupinama pacijenata koji su uzimali nisku i umjerenu dozu inhalacijskih kortikosteroida bio povećan (5,45% i 3,60%) u odnosu na skupinu bez terapije inhalacijskim kortikosteroidima, nije pronađena statistička značajna razlika u povećanju rizika među skupinama za prijelom kuka ili veliki osteoporotski prijelom (P=0,410 i P=0,328). Pacijenti koji su prema GOLD-u bili u skupini 3 i 4 nisu imali statistički značajno povećan rizik za prijelom kuka i veliki osteoporotski prijelom u odnosu na pacijente iz skupine 1 i 2 po GOLD-u (P=0,363 i P=0,644). Zaključci: Istraživanje je pokazalo da većina pacijenata s KOPB-om ima visoki rizik za prijelom kuka, ali ne i za veliki osteoporotski prijelom. Nije dokazan statistički značajno viši rizik prijeloma u pacijenata s visokim rizikom za razvoj akutnih egzacerbacija u odnosu na one s niskim rizikom. Također nije dokazan statistički značajno viši rizik prijeloma u onih koji uzimaju višu dnevnu dozu inhalacijskih kortikosteroida u odnosu na one s nižom dnevnom dozom ili na one bez inhalacijskih kortikosteroida u terapiji. Nije dokazan povećan rizik prijeloma u pacijenata s višim stupnjem bronhalne opstrukcije (skupine 3 i 4 po GOLD-u) u odnosu na one s nižim stupnjem (skupine 1 i 2 po GOLD-u). Da bi mogli donijeti ispravne zaključke potrebna su daljna istraživanja s većim brojem ispitanika.Cilj: Cilj ovoga rada bio je procijeniti rizik prijeloma u pacijenata s kroničnom opstrukcijskom plućnom bolesti (KOPB) s obzirom na specifične čimbenike rizika vezane uz bolest, a povezane s razvojem osteoporoze i prijeloma.
Abstract (english)
Objectives: The aim of this study was to assess fracture risk in patients with chronic opstructive pulmonary disease in relation to specific risk factors related to the disease, and responsible for the development of osteoporosis and fractures. Subjects and methods: The research was conducted at the Clinic for Lung Diseases of the University Hospital of Split during April and May 2021. 35 patients with COPD were included in this study. The data were collected by survey questionnaires and by examining medical documentation. Ten year fracture risk was calculated for each patient using the FRAX tool. Patients were compared by groups depending on the number of acute exacerbations in the previous year, the total daily dose of inhaled corticosteroids and the grade of airflow limitation classified by GOLD. Results: No statistically significant difference in hip fracture risk P=0.420 and major osteoporotic risk fracture P=0.398 was found comparing patients who had been at high risk for development of acute exacerbations with those at low risk. Although the risk for hip fracture in groups of patients on low and moderate dose of inhaled corticosteroids was increased (5.45% and 3.60%) in relation to group without inhaled corticosteroids, statistically there was no significant difference between groups for hip or major osteoporotic risk fracture (P=0.410 and P=0.328). Patients in GOLD groups 3 and 4 didn’t have a statistically significantly increased risk for hip fracture and major osteoporotic fracture compared to patients in GOLD groups 1 and 2 (P=0.363 and P=0.644). Conclusions: This research has shown that most COPD patients have a high risk for hip fracture, but not for a major osteoportic fracture. However, a statistically significantly greater risk wasn’t found in patients with high risk for development of acute exacerbations compared to low risk patients. Furthermore greater risk wasn’t found in patients on higher daily doses of inhaled corticosteroides opposite to those on low doses or those who didn’t take any inhaled corticosteroides. No increased risk of fractures was found in patients with higher (GOLD groups 3 and 4) compared to those with lower grade of airflow limitation (GOLD groups 1 and 2). Further research with a larger number of subjects is neccessary to draw correct conclusion.
Keywords
Keywords (english)
Languagecroatian
URN:NBNurn:nbn:hr:171:008510
Study programmeTitle: Medicine
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Terms of useLicence In copyright icon
Created on2021-08-27 07:17:38